Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis.

Autor: Noorani B; AbbVie, Inc., North Chicago, Illinois, USA., Menon RM; AbbVie, Inc., North Chicago, Illinois, USA., Chen X; AbbVie, Inc., North Chicago, Illinois, USA., Marsh KC; AbbVie, Inc., North Chicago, Illinois, USA., Huang W; Genentech Inc., South San Francisco, California, USA., Gupta S; AbbVie, Inc., North Chicago, Illinois, USA., Dobkowska E; Pharmacyclics, an AbbVie company in Switzerland, Schaffhausen, Switzerland., Marbury T; Orlando Clinical Research Center, Orlando, Florida, USA., Salem AH; Clinical Pharmacy, Ain Shams University, Cairo, Egypt.
Jazyk: angličtina
Zdroj: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Mar; Vol. 90 (3), pp. 748-758. Date of Electronic Publication: 2023 Nov 21.
DOI: 10.1111/bcp.15935
Abstrakt: Aims: Renal insufficiency is a common comorbidity in patients with haematological malignancies. This study aimed to assess how end-stage renal disease (ESRD) might affect the pharmacokinetics of venetoclax, a Bcl-2 inhibitor, in participants with ESRD undergoing haemodialysis.
Methods: Venetoclax was administered as a single 100-mg dose to 6 female participants with ESRD (estimated glomerular filtration rate <15 mL/min) both prior to haemodialysis and between haemodialysis days and 7 healthy female participants with normal renal function (estimated glomerular filtration rate >90 mL/min). Intensive pharmacokinetic and protein binding samples were collected from all participants. Arterial and venous samples were collected from ESRD participants during haemodialysis to assess the effect of haemodialysis on venetoclax pharmacokinetics. Pharmacokinetic parameters were estimated using noncompartmental methods.
Results: There was no difference in plasma venetoclax concentrations between arterial and venous samples, suggesting that haemodialysis did not affect the pharmacokinetics of venetoclax. The fraction unbound (f u ) of venetoclax was ~2-fold higher for participants with ESRD compared to participants with normal renal function. The unbound maximum plasma concentration and area under the plasma concentration-time curve from time 0 to 48 h were comparable between ESRD and normal function groups. The mean half-life ranged from 10.4 to 12.2 h across groups, demonstrating that ESRD did not affect the half-life of venetoclax. No new safety signals were observed during this study.
Conclusion: ESRD and dialysis do not alter unbound venetoclax plasma concentrations. No pharmacokinetics driven dose adjustment is needed for patients with renal insufficiency.
(© 2023 British Pharmacological Society.)
Databáze: MEDLINE
Externí odkaz: